Pseudomonas cepacia, a phytopathogen first described as the cause of soft rot of onions (4) , is now recognized as a significant opportunistic pathogen in patients with nosocomial infections (9, 12) . Patients with cystic fibrosis (CF) appear to be particularly susceptible to pulmonary colonization with this organism (2, 13, 23, 25) : CF patients colonized with P. cepacia experience more pulmonary exacerbations and a higher mortality than do noncolonized CF patients (26) .
P. cepacia is innately resistant to a wide range of antibiotics and disinfectants including polymyxin, aminoglycosides, and traditional antipseudomonal penicillins such as ticarcillin (3, 7, 15, 21) . It is not surprising, therefore, that P. cepacia infections are generally refractory to antibiotic therapy and pose a significant challenge in the management of patients with CF (9, 10). Historically, the most effective antibiotics for the treatment of P. cepacia infections were trimethoprim-sulfamethoxazole and chloramphenicol, although these agents displayed limited clinical efficacy (20, 27) . More recently available antibiotics, including ceftazidime, temocillin, imipenem, and ciprofloxacin, exhibit some in vitro activity against this organism (1, 17, 26) . However, initial clinical experience with some of these compounds has shown variable benefits (8) .
The availability of new agents with in vitro and in vivo activities against P. cepacia would be of considerable importance in the management of patients with CF. Thus, we examined a new carbapenem, meropenem, and two more recently developed quinolones for their activities against a large collection of P. cepacia isolates, including those from patients with CF.
Meropenem (ICI 194660 or SM 7338) is a new carbapenem with an exceptionally broad spectrum of antibacterial activity (14) . Unlike imipenem, which is metabolized by renal dipeptidases and requires the coadministration of cilastatin, meropenem is stable to dehydropeptidase-I, and thus, it is not necessary to coadminister it with cilastatin (6, 18) . PD 127391, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4,dihydro-4-oxo-3-quinolone-carboxylic acid, and * Corresponding author.
PD 131628, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, are oral quinolones that are being developed by WarnerLambert and that may possess pharmacokinetics superior to those of clinically available 4-quinolones (5, 16) . The data presented here describe the in vitro activities of these compounds against P. cepacia compared with those of the most active antibiotics available, ceftazidime, ciprofloxacin, chloramphenicol, and trimethoprim-sulfamethoxazole (cotrimoxazole). Most previous in vitro studies of the activity of meropenem and the two PD compounds have tested only small numbers of P. cepacia or used collections of pseudomonads which were not identified to the species level (5, 14, 16) .
In the present study, we investigated a total of 130 P. cepacia isolated from CF and non-CF patients in France, the United Kingdom, and the United States. All strains were identified by standard methods (11) , including use of the API 20NE system (API System, La Balme les Grottes, France) and determination of their ability to grow on a selective medium (7) . The strains included in the study were further characterized by bacteriocin typing (11, 22) ; multiple isolates from individual patients or epidemics belonging to the same bacteriocin type were excluded from the study. The antibiotics used in the study were None of the presently available antimicrobial agents has proved to be effective in the treatment of P. cepacia colonization in patients with CF, although combination therapy with temocillin and an aminoglycoside has been reported to have some clinical effect even against aminoglycoside-resistant isolates (27) cepacia from patients with CF examined in the present study were susceptible. If the upper limit of susceptibility for the PD compounds is put at 2 to 4 ,ug/ml, as suggested for similar compounds (28) , PD 127391, with an MIC50 of 4 ,ug/ml and an MIC range of 0.12 to 32 ,ug/ml, appears marginally better than PD 131628 and the existing quinolone standard ciprofloxacin.
It is a cause of concern that two strains of P. cepacia that exhibited resistance to all seven antibiotics tested were isolated from two patients with CF in Wales and Scotland. Further investigation of the prevalence of such multiresistant strains is needed to assess future problems in the management of patients with CF. The MIC data indicate that, with the exception of the two isolates from patients with CF in Wales and Scotland, meropenem and the PD compounds are highly active against isolates of P. cepacia that are resistant to the four other antibacterial agents investigated.
We conclude that the overall activities of meropenem and the PD compounds in in vitro susceptibility tests against a comprehensive collection of P. cepacia isolates indicate that these are promising new agents and that further studies of their pharmacokinetics and clinical efficacies in patients with CF are needed.
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